Conserved Protein Domain Family
7tmA_P2Y1-like

?
cd15967: 7tmA_P2Y1-like 
P2Y purinoceptor 1-like
P2Y1-like is an uncharacterized group that is phylogenetically related to a family of purinergic G protein-coupled receptors. The P2Y receptor family is composed of eight subtypes, which are activated by naturally occurring extracellular nucleotides such as ATP, ADP, UTP, UDP, and UDP-glucose. These eight receptors are ubiquitous in human tissues and can be further classified into two subfamilies based on sequence homology and second messenger coupling: a subfamily of five P2Y1-like receptors (P2Y1, P2Y2, P2Y4, P2Y6, and P2Y11Rs) that are coupled to G(q) protein to activate phospholipase C (PLC) and a second subfamily of three P2Y12-like receptors (P2Y12, P2YR13, and P2Y14Rs) that are coupled to G(i) protein to inhibit adenylate cyclase. Several cloned subtypes, such as P2Y3, P2Y5, and P2Y7-10, are not functional mammalian nucleotide receptors. The native agonists for P2Y receptors are: ATP (P2Y2, P2Y12), ADP (P2Y1, P2Y12, and P2Y13), UTP (P2Y2, P2Y4), UDP (P2Y6, P2Y14), and UDP-glucose (P2Y14).
Statistics
?
PSSM-Id: 320633
View PSSM: cd15967
Aligned: 8 rows
Threshold Bit Score: 453.379
Threshold Setting Gi: 632939955
Created: 3-Nov-2014
Updated: 26-Jul-2017
Structure
?
Aligned Rows:
  next features
Feature 1:putative ligand binding pocket [chemical binding site]
Evidence:
  • Comment:partly based on the structure of human P2Y1 receptor with bound nucleotide antagonist MRS2500
  • Comment:also based on the structures of some class A family members with bound ligands (peptides or chemicals), agonists, or antagonists
  • Comment:Small-molecule chemical ligands tend to bind deeper within the receptor core, compared to a peptide ligand neurotensin, which binds towards the extracelllular surface of its receptor.

Sequence Alignment
?
Format: Row Display: Color Bits: Type Selection:
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
Feature 1                                                               #  ##            ###### #
gi 209737342  25 SFLPAVFMLVFVVGTFANFCGLKTVCTSWKkigsINIFILNLGVADLLYLFTLPFLVVYYAlnskWIFGqtfCKITRFCF 104
gi 483516964  19 HFLPGVYLVVIPLGLVGNVLGLWHLRAAPHg--pLSLLVGNLGLADLLYVGTLPFLVGYYLrgraWPFGrawCRLTRSLF 96
gi 642128397  17 TFLPTVYMSVFIVGLVGNCWGLKSLFANWKkfgnINIFVLNLGVADILYLLTLPFLFAYYSagshWAFGqvfCKMTRFCF 96
gi 658860158  17 TILPTLYILVFVVGLVLNVWGMKSLLHNWKklqsINIFVLNLGLADILYLLTHPFLIMYYLkenkWIFGdgfCKVTRFCF 96
gi 47229090  374 RFLPPIYICVFVVGLLANGWGLSSLLKNWKklgnINLFVLNLGISDVLYLLTLPFLMVYYWks-qWIFGqtfCKVTRFCF 452
gi 632939955  15 QYLPPIYIMVFVVGFLGNCWALLSMRFHRVkwtgINVFLCNLALADLLYVITLPFLVVYYAsrghWIFGtvfCRATRLLF 94
gi 432867157  15 QFLPPVYICVFIVGLLANIWALECLLHNWKkigcVNVFVLNLGLADILYLLTLPFLMVYYIkg-cWMFGqihCKITRFFF 93
gi 432867209  73 KLLPALYTITFIIGFVGNAWGLKLLLQKWQklgnINVFVLNLGLANVLYLFTIPFLMVYYFsgrkWIFGdifCKMTRFCF 152
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
Feature 1        #  #                                             # #####               # ###    
gi 209737342 105 NLNLYCSIGFLTCISIYRYLGIVHPmkVMGKIh-tRHSVAISFLVWILVFIQILPDMFfdkta---qnspYSCYDStand 180
gi 483516964  97 HLNLYASIGFLTCISLHRYLGIVHPlrARGRCqelFSSAWLSAAVWGWVVAQVAPDLAfskm----nsngTQCHDTteqd 172
gi 642128397  97 NLNLYGSIGFLTCISVYRYLSIVHPlrVMGRIt-rGHSVVITAVVWGLVCIEIIPDLFfdktllnsssgkVKCVDTtfnf 175
gi 658860158  97 NLNLYGSIGFLTCISVYRYLAVVHPmrTMGRLt-tTHSVIISAIVWILVSAQSLPDLFyqkt----ypngSKCFDTtsne 171
gi 47229090  453 NLNLFGSMAFLAWISVYRYLAIVHPvmAMGRIt-pTHSALISVATWLLVGIQCLPDMFytktr---rsgtEACFDTtdqk 528
gi 632939955  95 HLNLHGSIGFLTCISVQRYLGIVHPmrVLGRVk-tHHSVVTSVVVWLVVVIQTATDLYfskt----npnsTKCYDTtfdd 169
gi 432867157  94 SVNLYCSIAFLTCISVYRYLAIVHPmrVHGRMt-vTRSAVISALVWILAILQSLPDVFflkt----dddnSGCFDTttnd 168
gi 432867209 153 NVNLYCSIGFLTCISVYRYLAIVHPlrMMGRLt-vTHSVLISVLVWLLVSVQSMPDIFfpks----vngtEKCFHStsre 227
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
Feature 1            #  ### ### ##                                              #  ## ##  #      
gi 209737342 181 fikdYLSYSIGWTITGFVIPLLIILACYGHIVVVLatkanvntLLKQRCLKLVIILTVLFSICFIPYHVLRNLNLkiril 260
gi 483516964 173 nlgsYLAYTAAVTATGFVVPFLIIIGCYCHVVVVLcrndtmdpGLRRRSIRLVVLVMVLFSVCFLPYHVFRNLNLlsrrw 252
gi 642128397 176 stkeYLDYSIAWTVSGFFIPLLIILGCYGHVAVVLfnnpnidqVMKQRCLKLVIIVTLLFSVCYIPYHIFRNLNLktril 255
gi 658860158 172 hiksYLDYSITWTFFGFCIPFAIIVGCYGLVALVIcrsdkmkkDLKQRFLKLMFFLILLFSICYAPYHVFKNLSLysrtl 251
gi 47229090  529 yvesYLKYSLGWTSAGFGIPLLVTLGCYGHMFVVLcrknttdkVLKQKCMKLLVILILLFSVCYIPYHVLKNLNLwsrll 608
gi 632939955 170 alpaYITYSLTLSVVGFLLPFAITLGCYAHVVVVLtrnpnvdpILKSRCLRLVAIVTVLFSFCFTPYHVLRNANLlaryl 249
gi 432867157 169 yvenYLMYSLGWTLSGFVIPTFITLGCYGHIIVVLclknnvdkGLKERTLKLMIVLIVLFSVCYIPYHVFKNLNLwsrvl 248
gi 432867209 228 ktedYLTYSLVWTTTGFCIPLLVTLGCYGHVTFVLcrrntiekTLRQKCVKFLFILILLFSVCYIPYHVFRNLSLfsriq 307
                        250       260       270       280
                 ....*....|....*....|....*....|....*....|....*.
Feature 1                    ## ###  #  ##                     
gi 209737342 261 kmegtckasfddIYVAHQISRGLVCMNSAINPLIYLVGNddFIMRF 306
gi 483516964 253 qqqgsctqasrdIYVSYQVTRGLASFNSALNPLLYVMTSkdCTSRV 298
gi 642128397 256 kskgtcedwfagIYIAHQVSRSLVCLNSAINPLVYIHSNenLLVHI 301
gi 658860158 252 skekqcttwdsgVFIARQASRGLVSLNSALNPLVYLNVNkdMGVQF 297
gi 47229090  609 sswkvcrkwadsVYIAQQLSRGLVCLNSALNPLVYLRGDenILASL 654
gi 632939955 250 qlqgsctrtsraIYMAYQVSRGLASLNSAINPLVYFIAGdeIKSRM 295
gi 432867157 249 qkqdkcyewfngIYIGHQIGRGMACLNSALNPLVYLFVSedIAIKI 294
gi 432867209 308 skqnicvwwdkhVFTGHQISRGLVCLNSALNPLVYLQMSehILTHI 353

| Disclaimer | Privacy statement | Accessibility |
NCBI Home NCBI Search NCBI SiteMap